reports
Corvus Pharmaceuticals Provides Business Update and Reports Second Qua...
Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results Soquelitinib data from cohort 3 of atopic dermatitis Phase 1 clinical trial demonstrates earlier and deeper responses compared to cohorts 1-2 along with clinically meaningful reduction in itch as early as day 8 Enrollment ongoing in Phase 1 trial extension cohort 4 exploring the same cohort 3 dose (200 mg BID) for a longer 8-week treatment period; Phase 2 trial on track to initiate before end of year Phase 3 registrational clinical trial of soquelitinib in relapsed/refractory peripheral T ce...
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2...
Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025 Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on August 7, 2025 at 4:30 pm ET (1:30 pm PT) to provide a business update and report second quarter 2025 financial results. The conference call can be accessed by dialing 1-800-717-173...
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Receive...
Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis Trial will be conducted by Angel Pharma and will study 12-week dosing of soquelitinib in patients with moderate-to-severe atopic dermatitis SOUTH SAN FRANCISCO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the IND application submitted by its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), h...
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highligh...
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress SOUTH SAN FRANCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced preclinical data highlighting the potential of soquelitinib to treat systemic sclerosis will be presented today in a poster session at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress, which is taking place June 11-14, 2025 in Barcelona. The pos...
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Co...
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo with statistically significant difference from placebo at day 28 Cohort 3 demonstrates clinically meaningful reduction in itch as early as day 8 Enrollment initiated in extension cohort study exploring the same cohort 3 dose (200 mg BID) for a longer 8-week treatment period SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE N...
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthc...
Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the 2025 Jefferies Global Healthcare Conference, which is being held in New York, NY. The presentation will be on Thursday, June 5 from 9:20-9:50 am ET. A webcast of the presentation will be available live and for 90 days ...
Corvus Pharmaceuticals Provides Business Update and Reports First Quar...
Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Phase 3 registrational clinical trial of soquelitinib in peripheral T cell lymphoma (PTCL) enrolling with multiple clinical sites open Early exercise of common stock warrants by stockholders providing cash proceeds of approximately $31.3 million Soquelitinib data to be highlighted on confere...
Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Cont...
Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis Data continue to demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Data to be presented in an oral session and poster at the Society for Investigative Dermatology 2025 Annual Meeting Company to discuss data today on its first quarter 2025 business update conference call and webcast at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Corvus...
Corvus Pharmaceuticals to Present New Interim Data from Placebo-Contro...
Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025 Data from Cohorts 1-3 of trial to be presented in an oral session and poster at the Society for Investigative Dermatology (SID) 2025 Annual Meeting Company to discuss data on its first quarter 2025 business update conference call and webcast scheduled for 4:30 pm ET / 1:30 pm PT on May 8, 2025 SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical com...
Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of D...
Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that Richard van den Broek, managing partner at HSMR Advisors, has been appointed to the Company’s board of directors. Mr. van den Broek has more than 30 years of experience in the life sciences industry as an investor, biotechnology equity research analyst and board member. “We’re thrilled to welcome Richard to our board,” said Richard A. Mill...
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Qua...
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results Soquelitinib Atopic Dermatitis Phase 1 Clinical Trial Data From Cohorts 1-3 anticipated to be Presented in May Initial Results From First Two Cohorts Supports Safety and Efficacy with Oral Agent and Novel Mechanism of Action Registration Phase 3 Clinical Trial of Soquelitinib in Peripheral T Cell Lymphoma (PTCL) Enrolling with Multiple Clinical Sites Open Conference call today at 4:30 p.m. ET / 1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Corv...
Corvus Pharmaceuticals Announces Presentation of Additional Data from ...
Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma Data to be presented in oral session and poster at the 16th Annual T-Cell Lymphoma Forum SOUTH SAN FRANCISCO, Calif., March 20, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that additional data from the Company’s Phase 1/1b clinical trial of soquelitinib for the treatment of patients with T cell lymphoma (TCL) is being presented at the 16th Annual T-Cell L...
Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Au...
Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference, which is being held virtually. The fireside chat will be on Thursday, March 27, 2025 ...
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter a...
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 25, 2025 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter and full year 2024 financial results. The conference call can be access...
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial ...
Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) Trial for this rare genetic disease to be conducted by NIH/NIAID in partnership with Corvus ITK inhibition intended to address dysregulation of T cells that causes ALPS and has been shown to be effective at treating the disease in preclinical models BURLINGAME, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the National Institute of A...
Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healt...
Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference BURLINGAME, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, which is being held virtually. The presentation will be on Tuesday, February 11, 2025 at 9:20 am ET. A webcast of the presentation will be available ...
Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Control...
Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis Data continue to demonstrate a favorable safety and efficacy profile, including improvements in IGA 0 or 1 and EASI 75 scores compared to placebo BURLINGAME, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe...
Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healt...
Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference BURLINGAME, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that Richard A. Miller, M.D., president and chief executive officer, will conduct one-on-one meetings with investors and present a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference, which is being held in San Francisco from January 13-16, 2025. The Company’s presentation will be on Wednesday, January 15 at 2:15 pm ET / 11:15 ...
Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled ...
Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis Data from lowest dose level cohorts demonstrate a favorable safety and efficacy profile Data includes complete results from cohort 1 and initial results from cohort 2 Early exercise of common stock warrants from stockholder generates cash proceeds of approximately $12.7 million Company to host conference call and webcast today at 8:00 a.m. ET / 5:00 a.m. PT BURLINGAME, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: ...
Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlle...
Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024 Company to host conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT on Wednesday, December 18, 2024 BURLINGAME, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, will announce interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis tomorro...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.